Table 2. Risk of Any Immune-Related Adverse Events Associated With Each Treatment Regimena.
| Treatment regimen | Odds ratio (95% CrI) | |||||||
|---|---|---|---|---|---|---|---|---|
| Chemotherapyb | Ipilimumab | Pembrolizumab, 10 mg/kg, every 2wk | Nivolumab, 1 mg/kg, every 3 wk + ipilimumab 3 mg/kg every 3 wk | Nivolumab, 3 mg/kg, every 2 wk | Pembrolizumab | |||
| 3 mg/kg every 3wk | 10 mg/kg every 3wk | 10 mg/kg every 3 wk | 2 mg/kg every 3wk | |||||
| Chemotherapyb | NA | 1.13 (0.37-3.26) | 0.50 (0.15-1.72) | 0.79 (0.14-4.19) | 0.79 (0.14-4.19) | 1.44 (0.63-3.4) | 1.21 (0.41-3.49) | 1.74 (0.48-6.67) |
| Ipilimumab | ||||||||
| 3 mg/kg every 3 wk | 0.88 (0.30-2.70) | NA | 0.44 (0.2-1.04) | 0.71 (0.19-2.59) | 0.71 (0.19-2.59) | 1.29 (0.54-3.27) | 1.08 (0.38-3.14) | 1.55 (0.31-8.7) |
| 10 mg/kg every 3wk | 2.00 (0.58-6.45) | 2.27 (0.94-4.96) | NA | 1.60 (0.33-7.09) | 1.60 (0.33-7.09) | 2.91 (1.09-7.55)c | 2.44 (0.68-8.36) | 3.51 (0.62-20.48) |
| Pembrolizumab, 10 mg/kg, every 2 wk | 1.25 (0.23-6.81) | 1.42 (0.37-5.31) | 0.62 (0.14-3.07) | NA | 0.60 (0.13-3.67) | 1.83 (0.39-9.23) | 1.52 (0.29-7.99) | 2.19 (0.28-18.94) |
| Nivolumab | ||||||||
| 1 mg/kg every 3 wk and ipilimumab, 3 mg/kg, every 3 wk | 2.05 (0.38-8.26) | 2.31 (0.70-6.04) | 1.02 (0.25-3.61) | 1.66 (0.26-7.75) | NA | 3.05 (0.7-10.59) | 2.55 (0.51-9.88) | 3.67 (0.46-23.96) |
| 3 mg/kg every 2 wk | 0.69 (0.29-1.60) | 0.78 (0.30-1.90) | 0.34 (0.13-0.94)c | 0.55 (0.11-2.67) | 0.33 (0.09-1.57) | NA | 0.84 (0.27-2.55) | 1.20 (0.27-5.83) |
| Pembrolizumab | ||||||||
| 10 mg/kg every 3 wk | 0.82 (0.28-2.44) | 0.93 (0.32-2.67) | 0.41 (0.12-1.50) | 0.66 (0.12-3.56) | 0.40 (0.10-2.08) | 1.19 (0.38-3.81) | NA | 1.44 (0.29-7.89) |
| 2 mg/kg every 3 wk | 0.58 (0.14-2.16) | 0.65 (0.11-3.43) | 0.29 (0.05-1.70) | 0.46 (0.05-3.84) | 0.28 (0.04-2.30) | 0.84 (0.17-3.88) | 0.70 (0.13-3.79) | NA |
Abbreviations: CrI, credible interval; NA, not applicable.
a
The pooled odds ratios (95% CrIs) were the result of comparing the left-column treatment regimens with the top-row treatment regimens (the reference group).
b
Immune-related adverse events were the outcomes associated with immune checkpoint inhibitors, not chemotherapy drugs (ie, carboplatin, dacarbazine, and paclitaxel). For chemotherapy users, the adverse events identified were associated with chemotherapy. The pooled odds ratios were estimated from all direct and indirect comparisons.
c
Statistically significant.